Johnson & Johnson Development Corporation and Atlas Venture both returned to contribute to a $12.9m round raised by the pharmaceutical company.
Johnson & Johnson Development Corporation (JJDC), the corporate venturing subsidiary of healthcare company Johnson & Johnson, and venture capital firm Atlas Venture have co-led a $12.9m series A round for pharmaeutical company Rodin Therapeutics.
US-based Rodin, a biotechnology company specialising in combating neurological disorders through epigenetics, will use the funds to develop its selective epigenetic modulators.
Bruce Booth, Rodin’s chairman and acting CEO, and also a partner at Atlas Venture, said: “Rodin has spent the last year validating the thesis…
